Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.

doi:10.1158/1535-7163.MCT-09-0665

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.

Molecular cancer therapeutics - 1 Mar 2010

Giovannetti Elisa, Zucali Paolo A, Peters Godefridus J, Cortesi Filippo, D'Incecco Armida, Smit Egbert F, Falcone Alfredo, Burgers Jacobus A, Santoro Armando, Danesi Romano, Giaccone Giuseppe, Tibaldi Carmelo

Abstract excerpt

EGFR mutations are strongly predictive of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor activity in non-small cell lung cancer (NSCLC), but resistance mechanisms are not completely understood. The interindividual variability in toxicity also points out to the need of novel pharmacogenetic markers to select patients before therapy. Therefore, we evaluated the associations between EGFR and AKT1...

Topics

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Biomarkers, Pharmacological
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
Drug-Related Side Effects and Adverse Reactions
ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Gefitinib

Humans

Lung Neoplasms

Male

Middle Aged

Polymorphism, Single Nucleotide

Prognosis

Proto-Oncogene Proteins c-akt

Source

Open in PubMed

Identifiers

PMID: 20159991
DOI: 10.1158/1535-7163.MCT-09-0665

Genes

EGFR
AKT1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-20159991-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.PMID 20159991Read ↗

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

AKT1 polymorphisms and survival of early stage non-small cell lung cancer.Semantic proximity Read ↗

Impact of glutathione S transferases P1 (Ile105Val) variants on the risk of GSTp, phosphorylated c-Jun kinase, and P53 phenotypic expression and their implications on overall survival outcomes in non-small cell lung cancer patients treated with chemotherapy.Semantic proximity Read ↗

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinibSemantic proximity Read ↗

Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy.Semantic proximity Read ↗

PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.Semantic proximity Read ↗

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.Semantic proximity Read ↗

Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.Semantic proximity Read ↗

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.Semantic proximity Read ↗

Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.Semantic proximity Read ↗

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.